Wu; Xihan

Patent Applications and Registrations

Patent applications and USPTO patent grants for Wu; Xihan.The latest application filed is for "pyrrolo[2, 1-f] [1,2,4]triazine derivative and use thereof for treating tumors".

Company Profile

0.15.17

Wu; Xihan - Jiangsu CN
Wu; Xihan - Nanjing CN
Wu; Xihan - Shanghai CN

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Pyrrolo[2, 1-F] [1,2,4]triazine derivative and use thereof for treating tumors Grant 9,440,981 - Wu , et al. September 13, 2	2016-09-13
Antitumor aza-benzo [f] azulen derivative, method for preparing same, and use thereof Grant 9,382,249 - Wu , et al. July 5, 2	2016-07-05
Pyrrolo[2, 1-f] [1,2,4]triazine Derivative And Use Thereof For Treating Tumors App 20160115166 - Wu; Xihan ; et al.	2016-04-28
Method for synthesizing 1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-formamidine hydrochloride Grant 8,957,210 - Li , et al. February 17, 2	2015-02-17
Antitumor Aza-benzo [f] Azulen Derivative, Method For Preparing Same, And Use Thereof App 20150011536 - Wu; Xihan ; et al.	2015-01-08
Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease Grant 8,871,756 - Chen , et al. October 28, 2	2014-10-28
Method For Synthesizing 1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridine-3-formamidine Hydrochloride App 20140309425 - Li; Jin ; et al.	2014-10-16
Compounds For The Treatment And Prophylaxis Of Respiratory Syncytial Virus Disease App 20130196974 - Chen; Li ; et al.	2013-08-01
Ortho-aminoanilides for the treatment of cancer Grant 8,202,866 - Liang , et al. June 19, 2	2012-06-19
Pyrrolidine aryl-ether as NK-3 receptor antagonists Grant 8,012,998 - Jablonski , et al. September 6, 2	2011-09-06
N-(2-amino-phenyl)-acrylamides Grant 7,999,000 - Wong , et al. August 16, 2	2011-08-16
Ortho aminoamides for the treatment of cancer Grant 7,977,372 - Liang , et al. July 12, 2	2011-07-12
Pyrrolidine derivatives as dual NK1/NK3 receptor antagonists Grant 7,893,062 - Bissantz , et al. February 22, 2	2011-02-22
Piperidine Derivatives As Nk3 Antagonists App 20110021565 - Knust; Henner ; et al.	2011-01-27
Pyrrolidine aryl-ether as NK3 receptor antagonists Grant 7,812,021 - Jablonski , et al. October 12, 2	2010-10-12
Ortho Aminoamides For The Treatment Of Cancer App 20100216806 - Liang; Chungen ; et al.	2010-08-26
Novel Ortho-aminoanilides For The Treatment Of Cancer App 20100069328 - Liang; Chungen ; et al.	2010-03-18
Novel N-(2-amino-phenyl)-acrylamides App 20090286848 - Wong; Jason Christopher ; et al.	2009-11-19
Piperazine and [1,4]diazepan derivatives as NK antagonists Grant 7,592,345 - Knust , et al. September 22, 2	2009-09-22
Isoquinoline aminopyrazole derivatives Grant 7,572,809 - Chen , et al. August 11, 2	2009-08-11
Prolinamide derivatives as NK3 antagonists Grant 7,528,136 - Han , et al. May 5, 2	2009-05-05
Piperidine Derivatives As Nk3 Antagonists App 20090076081 - Knust; Henner ; et al.	2009-03-19
Prolinamide-tetrazole derivatives as NK3 receptor antagonists Grant 7,501,422 - Han , et al. March 10, 2	2009-03-10
Pyrrolidine Aryl-ether As Nk3 Receptor Antagonists App 20090054644 - Jablonski; Philippe ; et al.	2009-02-26
Pyrrolidine Aryl-ether As Nk3 Receptor Antagonists App 20090042896 - Jablonski; Philippe ; et al.	2009-02-12
Piperazine And [1,4]diazepan Derivatives As Nk Antagonists App 20080312216 - Knust; Henner ; et al.	2008-12-18
Prolinamide Derivatives As Nk3 Antagonists App 20080306086 - Han; Bo ; et al.	2008-12-11
Prolinamide-tetrazole Derivatives As Nk3 Receptor Antagonists App 20080306089 - Han; Bo ; et al.	2008-12-11
Pyrrolidine Derivatives As Dual Nk1/nk3 Receptor Antagonists App 20080275021 - Bissantz; Caterina ; et al.	2008-11-06
Isoquinoline aminopyrazole derivatives App 20070179151 - Chen; Li ; et al.	2007-08-02

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.